Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VAR2CSA peptide-decorated antigenic liposomes
- Development stage
- Preclinical
- Lead developer
- University of Alberta
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
VAR2CSA peptide-decorated antigenic liposomes is a preclinical multivalent peptide vaccine candidate being developed by the University of Alberta for the prevention of placental malaria. The vaccine consists of liposomes decorated with two conserved peptides, P6 (located in the DBL3X domain) and P10 (located in the DBL4epsilon domain), which map to conserved epitopes on the Plasmodium falciparum virulence factor VAR2CSA. These peptides are conjugated to a lipid linker via strain-promoted azide-alkyne cycloaddition chemistry. The liposomes encapsulate ovalbumin to enhance immunogenicity and incorporate the TLR4 agonist monophosphoryl lipid A (MPLA) as an adjuvant. The vaccine is designed to induce synergistic inhibitory antibodies that prevent the binding of infected red blood cells to chondroitin sulfate A (CSA) in the placenta.
- Other names
- peptide-decorated antigenic liposomesVAR2CSA peptide-decorated liposomesVAR-2CSA peptide-decorated liposomesVAR 2CSA peptide-decorated liposomes
02
Targets
VAR2CSA
Beyond the preview
Go deeper on VAR2CSA peptide-decorated antigenic liposomes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VAR2CSA peptide-decorated antigenic liposomes.